Levi & Korsinsky Notifies Shareholders of Verve Therapeutics, Inc.(VERV) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / September 25, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Verve Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV
NEW YORK, NY / ACCESSWIRE / September 25, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Verve Therapeutics Inc Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 9, 2022, and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics Lawsuit - VERV
NEW YORK, NY / ACCESSWIRE / September 25, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Verve Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - VERV
NEW YORK, NY / ACCESSWIRE / September 25, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / September 25, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Verve Therapeutics, Inc. ("Verve Therapeutics" or "the Company") (NASDAQ:VERV) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Verve Therapeutics securities between August 9, 2022, and April 1, 2024, inclusive (the "Class Period").
Levi & Korsinsky Reminds Verve Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Investors in Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
The Schall Law Firm Encourages Investors To Participate In A Securities Fraud Case Against Verve Therapeutics, Inc.
LOS ANGELES, CA / ACCESSWIRE / September 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 9, 2022, and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.
Investors who Lost Money on Verve Therapeutics, Inc. (VERV) Should Contact Levi & Korsinsky About Pending Class Action - VERV
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics Lawsuit - VERV
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / September 24, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Verve Therapeutics, Inc. ("Verve Therapeutics" or "the Company") (NASDAQ:VERV) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Verve Therapeutics securities between August 9, 2022, and April 1, 2024, inclusive (the "Class Period").
